Pyrilutamide, also known as KX-826 and pyri, is a drug under development by Kintor Pharmaceutical (Kintor). Kintor Pharma is a clinical-stage company focused on discovering and developing novel small molecule therapeutics targeting cancer and other androgen receptor related diseases.
GlobalData tracks drugs through their clinical development, providing drug-specific PTSR and LoA benchmarks. To learn more about the PTSR and LoA of Pyrilutamide, purchase our full report here.
What is Pyrilutamide?
Pyrilutamide is a high-affinity, silent antagonist of the androgen receptor and has been in development for hair loss by Kintor Pharmaceuticals. It is an oral medication that may be able to treat both male and female pattern hair loss by blocking the androgen receptors in the scalp.
In a press release today, Kintor Pharmaceuticals announced that their phase 2 clinical trial of Buy pyrilutamide Europe for androgenetic alopecia in China had successfully concluded. The company also stated that they would start a phase 3 trial of the drug in the US next year (2021).
This trial will be randomized, double-blind, and vehicle-controlled to observe a change in non-vellus target area hair count over 6 months. It will be interesting to see how well this drug compares to finasteride once it becomes available on the market. PyriPure contains pure pyrilutamide (developmental codename KX-826) in a propylene glycol and ethanol solution. Each batch of PyriPure is tested and confirmed to be >99% pure by a professional testing lab.
Who should take Pyrilutamide?
Pyrilutamide is a topical anti-androgen and clinical trials indicate that it can be used as an alternative to finasteride for men with androgenic alopecia. The drug is formulated as a solution to be applied directly to the scalp. It is likely that it will need to be left on for a period of time for it to be absorbed by the scalp and bind to the androgen receptors.
The phase II trial conducted by Kintor in China was small and has yet to be published, but it is expected that the company will start a larger scale, phase III trial next year (2021). This will give us an indication of how effective, safe, and tolerable this new medication may be when it becomes available.
If you’re interested in knowing more about the new and upcoming medications for hair loss, be sure to check out GlobalData’s comprehensive drug development reports. They include drug-specific PTSR and LoA benchmarks built off of 18 years of drug development data.
How to take Pyrilutamide?
Buy pyrilutamide in Europe is a topical anti-androgen that works by inhibiting the activity of androgen receptors. It is a high-affinity silent antagonist and binds to the androgen receptor without causing the side effects associated with oral 5-alpha reductase inhibitors such as decreased libido, erectile dysfunction, and depression.
It is being developed by Kintor Pharmaceuticals, a company focused on developing and commercializing innovative treatments for AR-related diseases with unmet medical needs such as androgenic alopecia and prostate cancer. It is undergoing phase II and III trials in both the US and China.
In a recent press release, Kintor stated that the phase 2 trial of pyrilutamide in AGA patients in China had been completed and showed promising efficacy and safety results. This is great news! The next step would be for them to submit the data from this trial to the FDA and move into a larger phase 3 trial.
Our Pyrilutamide (KX-826) is 100% pure and comes in a 0.5% solution in an air and light tight bottle. We test our raw material for purity to ensure it is >99% every batch. The product also comes with a calibrated dropper.
Where to buy Pyrilutamide?
Pyrilutamide, also known as KX-826, is a drug in development by Kintor Pharmaceuticals. It is being studied in a phase II clinical trial for the treatment of androgenic alopecia in males and females. It has a similar structure to RU58841, which is currently available on the market.
Kintor Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics to treat cancer and other androgen receptor-related disease areas that lack effective treatments. Its pipeline includes GT20029 (AR-PROTAC), pyrilutamide (KX-826), Proxalutamide, Destorsertib and others.
GlobalData’s Pyrilutamide LoA report provides comprehensive analysis of the drug’s Phase II clinical trials, enabling users to fully understand its potential to advance in the market. It provides drug-specific PTSR and LoA benchmarks built from 18 years of historic data, in addition to indication-specific PTSR and LoA score calculations. Buy the report now.